Research analysts at Lifesci Capital initiated coverage on shares of Kodiak Sciences (NASDAQ:KOD - Get Free Report) in a research note issued to investors on Thursday,Benzinga reports. The firm set an "outperform" rating and a $40.00 price target on the stock. Lifesci Capital's target price points to a potential upside of 133.78% from the stock's current price.
KOD has been the subject of several other research reports. Chardan Capital reaffirmed a "neutral" rating and set a $14.00 target price on shares of Kodiak Sciences in a research note on Monday, October 6th. Jefferies Financial Group initiated coverage on shares of Kodiak Sciences in a research note on Monday, September 22nd. They issued a "buy" rating and a $15.00 price objective for the company. Weiss Ratings reissued a "sell (e+)" rating on shares of Kodiak Sciences in a research note on Wednesday, October 8th. JPMorgan Chase & Co. raised shares of Kodiak Sciences from an "underweight" rating to a "neutral" rating and set a $15.00 price objective for the company in a research note on Thursday, August 14th. Finally, Barclays raised shares of Kodiak Sciences from an "underweight" rating to an "equal weight" rating and raised their price objective for the company from $7.00 to $17.00 in a research note on Thursday, September 25th. Two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $17.67.
Read Our Latest Stock Analysis on Kodiak Sciences
Kodiak Sciences Stock Down 5.2%
KOD stock traded down $0.94 during mid-day trading on Thursday, hitting $17.11. 852,915 shares of the company were exchanged, compared to its average volume of 552,617. The firm has a market capitalization of $903.75 million, a P/E ratio of -4.50 and a beta of 2.67. The business has a fifty day simple moving average of $12.04 and a 200-day simple moving average of $7.06. Kodiak Sciences has a 12-month low of $1.92 and a 12-month high of $19.39.
Kodiak Sciences (NASDAQ:KOD - Get Free Report) last announced its earnings results on Wednesday, August 13th. The company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.02). Research analysts predict that Kodiak Sciences will post -3.45 EPS for the current year.
Institutional Trading of Kodiak Sciences
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KOD. Adage Capital Partners GP L.L.C. raised its holdings in Kodiak Sciences by 55.1% during the second quarter. Adage Capital Partners GP L.L.C. now owns 2,055,707 shares of the company's stock worth $7,668,000 after purchasing an additional 730,000 shares in the last quarter. Acadian Asset Management LLC raised its holdings in Kodiak Sciences by 27.0% during the first quarter. Acadian Asset Management LLC now owns 1,946,134 shares of the company's stock worth $5,454,000 after purchasing an additional 413,821 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its holdings in Kodiak Sciences by 90.1% during the first quarter. Jacobs Levy Equity Management Inc. now owns 685,198 shares of the company's stock worth $1,922,000 after purchasing an additional 324,722 shares in the last quarter. Nantahala Capital Management LLC raised its holdings in Kodiak Sciences by 99.1% during the first quarter. Nantahala Capital Management LLC now owns 530,713 shares of the company's stock worth $1,489,000 after purchasing an additional 264,100 shares in the last quarter. Finally, ICONIQ Capital LLC raised its holdings in Kodiak Sciences by 24.6% during the first quarter. ICONIQ Capital LLC now owns 1,266,563 shares of the company's stock worth $3,559,000 after purchasing an additional 249,699 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company's stock.
Kodiak Sciences Company Profile
(
Get Free Report)
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kodiak Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.
While Kodiak Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
